FDA Awards Priority Review Voucher for Ebanga (Ansuvimab-Zykl) to Ridgeback Biotherapeutics
April 23, 2025
April 23, 2025
WASHINGTON, April 23 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration (FDA) announced the issuance of a priority review voucher to Ridgeback Biotherapeutics, LP, for its material threat medical countermeasure (MCM) product, EBANGA (ansuvimab-zykl) for injection.
The voucher was awarded following the product's approval for treating infections caused by the Zaire ebolavirus in both adult and pediatric patients, including neonates born to m . . .
The voucher was awarded following the product's approval for treating infections caused by the Zaire ebolavirus in both adult and pediatric patients, including neonates born to m . . .